Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Ziopharm Oncology — Q3 2020 Earnings Presentation
10 slides from Alaunos Therapeutics's earnings presentation, Nov 5, 2020
Slide 1: Third Quarter 2020 Financial Results and Update
Third Quarter 2020 Financial Results and Update 05 November 2020 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plan
Slide 3: Broad Pipeline of Oncology Innovation
Asset Indication Phase 1 Phase 2 Multiple solid tumors rGBM Combination with Libtayo® (Ziopharm sponsor) Combination with OPDIVO® (Ziopharm sponsor) rGBM rGBM Monotherapy expansion (Ziopharm sponsor) Ad-RTS-hIL-12 + veledimex Broad Pipeline of Oncology Innovation Sleeping Beauty TCR-T targeting neoa
Slide 4: Third Quarter Results and Update
Third Quarter Results and Update Response to COVID-19: Ziopharm employees primarily work remotely with exceptions such as in our laboratory; safely and advancing programs; adapting to pandemic Sleeping Beauty TCR-T Program: Ziopharm on track to file IND for library hotspot trial in Q1 2021 through b
Slide 5: Ziopharm's TCR-T Clinical Program – Library Hotspot Trial
Ziopharm’s TCR-T Clinical Program – Library “Hotspot” Trial First Clinical Program – Evaluating Ziopharm’s Existing TCR Library in Multiple Cancers Ziopharm’s TCR Library Clinical Trial Timing: On track to file IND in Q1 2021; begin dosing patients in mid-2021 Indications: gynecologic, colorectal, p
Slide 6: Ziopharm's TCR-T Clinical Program – Personalized TCR-T Trial
Ziopharm’s TCR-T Clinical Program – Personalized TCR-T Trial Second Clinical Program – Evaluating Personalized TCR Approach in Multiple Cancers Overview: Personalized approach evaluates therapies using patient-derived TCRs targeting neoantigens specific to each patient “TCRs from the patient, for th
Slide 7: Ziopharm's TCR-T Infrastructure
Ziopharm’s TCR-T Infrastructure Building TCR Library Library in-licensed from NCI; Approach validated by multiple publications and in-house team Already sufficient to begin clinical trial at MD Anderson Ziopharm has multiple avenues for expanding the number of TCRs in library; Will continue growing
Slide 8: Financial Snapshot: Cash of $135.5 million
Financial Snapshot: Cash of $135.5 million Selected Balance Sheet Data Cash and cash equivalents as of 9/30/20 $135.5 million At MD Anderson from prepayment for programs to be conducted by the Company as of 9/30/20 $11.4 million Cash resources of approximately $135.5 million, plus pre-paid balance a
Slide 9: Anticipated Milestones
Anticipated Milestones Present additional clinical data for Controlled IL-12 program at SNO 2020 Advance enrollment and dosing of DIPG patients in pediatric trial for Controlled IL-12 at multiple sites Commence patient dosing in allogeneic RPM CD19-specific CAR-T study; Initiated at MD Anderson Comp
Slide 10: Thank you
Ziopharm ONCOLOGY Thank you... 05 November 2020